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The P2Y12 receptor on platelets with which ADP interacts has an important role in promoting platelet function and thereby platelet
involvement in both haemostasis and thrombosis. Agents that act as antagonists at this receptor are thus likely to provide effective
antithrombotic therapy, provided that there are no adverse effects on haemostasis. Here we describe the ADP receptor antagonists that
are available and in development.We also consider their mode of action and ask whether there are additional mechanisms through
which they exert their inhibitory effects on platelet function.
Introduction
Adenosine diphosphate (ADP) interacts with two different
purinergic receptors on platelets, known as P2Y1 and P2Y12
(Figure 1).These are two receptors of the seven transmem-
brane (7TM) class of receptors [1]. Interaction with P2Y1
receptors initiates the platelet response while interaction
with P2Y12 receptors promotes the response. Blockade of
the effects of ADP at either of these receptors results in a
marked reduction in the overall effect of ADP on platelet
function [2, 3].
The initial response to ADP is a change in the shape of
the platelet whereby disc shaped cells convert into a
spherical form from which pseudopodia emerge. This
change, which is mediated by the P2Y1 receptor, involves
Ca2+ influx, intracellular Ca2+ mobilization and actin poly-
merization. Interaction of ADP with the P2Y12 receptor
results in inhibition of adenylate cyclase, which is accom-
panied by platelet aggregation [4]. The latter is mediated
by a change in conformation of glycoprotein complexes
on the platelet surface known as GPIIb/IIIa complexes,such
that they become receptors for fibrinogen (Figure 1).
Fibrinogen is a bivalent molecule present in high concen-
trations in blood plasma. Once bound to some of the
50 000–100 000 GPIIb/IIIa complexes on a single platelet,
fibrinogen links the GPIIb/IIIa on adjacent platelets
together. The result is that individual single platelets are
transformed into a large mass in which many hundreds of
thousands of platelets have aggregated together [5, 6].
ADP appears alongwith adenosine triphosphate (ATP) in
the circulation consequent to cell and tissue damage. ADP
can also be produced from ATP by the action of CD39 on
endothelium and white cells (Figure 1) [7, 8]. ATP itself can
also promote platelet function under certain conditions
through interaction with another purinergic receptor, the
P2X1 receptor [9].Other important agents that result in plate-
let activation and platelet aggregation are collagen and
thrombin. In addition to causing platelet shape change and
aggregation, collagen and thrombin promote secretion by
platelets of the contents of storage granules which include
ADP andATP.The ADP,acting via P2Y1 and P2Y12 receptors on
the platelet surface amplifies the effects of the primary
stimulus provided by the collagen or thrombin [10].
Other platelet functional responses that are amplified
by released ADP include synthesis of thromboxane A2
(TXA2), which also promotes platelet aggregation acting
via TP receptors (Figure 1) [11]. ADP also promotes secre-
tion of other materials from intracellular granules includ-
ing P-selectin which is the prime mediator of platelet
interactions with leucocytes [12]. In addition, platelet
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microparticles are formed which provide procoagulant
surfaces that accelerate the coagulation cascade [13]. Col-
lectively all these mechanisms contribute to haemostasis,
thrombosis and inflammation.
ADP is thus an important contributor to platelet func-
tion through the P2Y1 and P2Y12 receptors. Agents that
reduce the effects of ADP at either of these could provide
effective antithrombotic therapy.
P2Y1 antagonists
Studies in P2Y1 knockoutmice have shown that absence of
the P2Y1 receptor leads to impaired platelet aggregation in
response to ADP and resistance to thromboembolism [14,
15]. A number of pharmacological agents have been iden-
tified that act as platelet P2Y1 antagonists [16–21]. These
have been investigated experimentally and clear inhibition
of ADP-induced platelet function has been shown.
However, given the ubiquitous expression of P2Y1 recep-
tors in other tissues of the body, the clinical potential for
the P2Y1 receptor to be used as an antithrombotic target is
questionable [22]. As far as we are aware, there have been
no clinical studies evaluating the use of P2Y1 antagonists
as antithrombotic agents in human subjects.Consequently
this review will focus on P2Y12 receptor antagonists.
P2Y12 antagonists
There are several agents that interact with the P2Y12 recep-
tor on platelets, thereby reducing platelet function. Some
are already in use as antithrombotic agents and others are
in development. The drugs we will discuss here are clopi-
dogrel, prasugrel, ticagrelor, cangrelor and elinogrel.These
drugs are routinely used in conjunction with aspirin which
inhibits TXA2 synthesis in platelets and thus provides an
additional means of reducing platelet function.
Clopidogrel
The P2Y12 antagonist that is currently most widely used as
an antithrombotic agent is clopidogrel. It is recommended
in current clinical guidelines for prevention of further
thrombotic events following acute coronary syndrome
and ischaemic stroke [23]. Clopidogrel is a thienopyridine
and succeeded another thienopyridine, ticlopidine, which
has been withdrawn gradually from clinical use due to a
high incidence of haematological side effects including
thrombotic thrombocytopenic purpura, neutropenia and
aplastic anaemia [24].
Clopidogrel is a prodrug and its effects on platelets
following oral administration derive from generation
in vivo of an active metabolite [25]. This binds to P2Y12
receptors irreversibly, rendering the receptor unable to
respond to ADP, thus reducing platelet function. The irre-
versible effect at the P2Y12 receptor is consequent to cova-
lent binding to cysteine sulphydryl residues within the
receptor. Its effect on platelet function lasts for the lifetime
of the affected platelet, which is between 7 and 10 days.
Although it is clear that clopidogrel provides significant
protection against thrombotic episodes when adminis-
tered to patients at risk of thrombosis (e.g. the CAPRIE
study [26]) and especially when used in combination with
aspirin (e.g. the CURE study [27]) the drug does have some
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Some of the receptors and pathways involved in platelet aggregation.The points at which P2Y1 or P2Y12 antagonists and aspirin inhibit platelet aggregation
are shown
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drawbacks. Its onset of action as an inhibitor of platelet
function is rather slow following initiation of standard
therapy, taking several days for a full effect to be realized,
and also its inhibitory effects on platelet function are vari-
able in different people with some patients continuing to
have high platelet reactivity despite treatment.
Multiple factors may contribute to this high
on-clopidogrel platelet reactivity. Genetic factors include
polymorphisms of the ABCB1 gene affecting intesti-
nal absorption [28], and polymorphisms of hepatic
cytochromeP450enzymes includingCYP2C9andCYP2C19
that are involved in thegenerationof the clopidogrel active
metabolite [29]. Recently, variation in another enzyme,
paraoxonase-1, has been shown to affect clopidogrel
metabolism [30].Other factors that could affect clopidogrel
efficacy include body mass index, gender, ethnicity, and
comorbidities such as liver disease and insulin resistance.A
number of drug–drug interactions have also been impli-
cated [29]. As well as inter-individual variability, it has
recently been shown that there is also large intra-individual
variability in the response to clopidogrel during long term
therapy [31].
High on-clopidogrel platelet reactivity has been shown
to be an important predictor of adverse thrombotic
outcomes [32]. Hence it is important that this issue is
adequately addressed in clinical practice. Unfortunately,
despite some genetic associations, it is not easy to predict
how an individual will respond to clopidogrel due to the
multiple factors involved.Platelet function testingmethods
are nowbecoming available that enable the degree of anti-
platelet effect to be determined [33–36].
Recent clinical trials have looked at the effects of
increasing the dose of clopidogrel in patients with inad-
equate inhibition of platelet function on standard dose
treatment. In the recently published GRAVITAS trial [37], a
point of care platelet function test was used to identify
patients with high on-clopidogrel reactivity. In these
patients, a modest improvement in platelet inhibition was
noted when randomized to high dose clopidogrel treat-
ment compared with a comparison group receiving stan-
dard doses. Despite this, no difference in clinical outcome
between the groups was seen. It must be noted that
patients received different doses of aspirin in this trial, but
there were no data on whether these were equally ran-
domized between the groups. It is also possible that the
low event rate in the GRAVITAS trial may have masked any
difference in outcome. Also, as with previously published
data [38], some patients continued to have very high plate-
let reactivity on higher doses of clopidogrel in this study
[37], which may have skewed the outcome data.
Further work is needed to evaluate the potential use of
platelet function testing clinically. Questions have been
raised about defining the cut off for high platelet reactivity,
the optimal time of measuring platelet function on treat-
ment, and whether serial platelet function measurements
may be useful [39]. Patients with high on-clopidogrel
platelet reactivity may particularly benefit from newer,
more effective drugs. Encouraging results to this effect
have been seen in an earlier study where the use of
intensified platelet inhibition with the GPIIb/IIIa inhibitor
tirofiban was shown to improve significantly outcomes
in patients who had poor responsiveness to clopidogrel
as determined using point-of-care platelet function test-
ing [40]. Further clinical trials are underway evaluating
the potential role of personalized antiplatelet therapy
[39].
There is also an economic decision to be made when
deciding on antiplatelet treatment, because clopidogrel is
now widely available as various generic salt formulations
that are relatively inexpensive [41], whereas other more
effective antiplatelet agents and the newer P2Y12 inhibitors
(see below) would cost the health service much more to
administer. However despite introduction to the market,
there are very little data comparing the newer, generic
clopidogrel salts with the original clopidogrel bisulphate.
Some limited evidence from small studies on healthy
subjects have shown absence of an overall difference in
bioequivalence or antiplatelet effect of clopidogrel besy-
late compared with clopidogrel bisulphate [42–44].
However in one cross-over study it was shown that there
was marked inter- and intra-individual variability between
the two different clopidogrel salts [44], and there is a
general lack of patient data.We have been unable to find
any peer reviewed publications on other commercially
available clopidogrel salts, such as clopidogrel hydrochlo-
ride. The limited availability of data about formulations of
a drug that already shows notable variation in patient
response in its original form, is concerning. This also high-
lights the potential importance of platelet function testing
and monitoring of antiplatelet therapy.
In the future it is likely that platelet function testing will
become obligatory if only to ascertain which patients are
receiving adequate treatment on clopidogrel, which
patients in whom higher doses of clopidogrel might be
tried, and which patients would be best receiving a newer,
more expensive antiplatelet agent. Using platelet function
testing to tailor therapy according to each individual
patient’s response may offer a cost-effective strategy in
future antiplatelet therapy.
Prasugrel
Prasugrel is also a thienopyridine and prodrug which, like
clopidogrel, needs to be converted to an active metabolite
to effect inhibition of platelet function [45]. As with clopi-
dogrel, the prasugrel active metabolite binds to cysteine
sulphydryl groups in the P2Y12 receptors irreversibly,
rendering the receptors unable to respond to ADP and
producing inhibition of platelet function for the lifetime of
the affected platelet. Prasugrel differs from clopidogrel,
however, in that it has a more rapid onset of action after
oral administration, it achieves greater and more consis-
tent platelet inhibition in individual patients [46, 47] and
Anti-platelet therapy: ADP receptor antagonists
Br J Clin Pharmacol / 72:4 / 649
thus its antiplatelet effects aremuchmore predictable.This
is achieved mainly because the metabolism of the drug
differs from that of clopidogrel and far greater and more
predictable amounts of active metabolite are produced.
For example, polymorphisms in CYP2C9 and CYP2C19
genes do not affect prasugrel metabolism, unlike the
metabolism of clopidogrel described above [48].
All this translates into a more effective anti-thrombotic
therapy as compared with clopidogrel as revealed in
the TRITON-TIMI study [49]. This was a head-to-head
comparison of prasugrel and clopidogrel in patients with
acute coronary syndromes with scheduled percutaneous
coronary intervention (PCI).The group treatedwith prasug-
rel had a significantly better outcome in termsof a compos-
ite of adverse events comprising death from cardiovascular
causes, nonfatal myocardial infarction and nonfatal stroke
(hazard ratio 0.81, 95% confidence interval 0.73, 0.90, P <
0.001).Therewasalsoa significant reduction in stent throm-
bosis compared with the clopidogrel group, although this
was achieved at the expense of an increased incidence of
bleeding.The clinical benefit of prasugrel over clopidogrel
was particularly marked in patients with diabetes. It was
noted that risks of bleedingoutweighed the clinical benefit
in patients with a previous history of stroke, the elderly
(75 years), and those with a body weight of less than
60 kg.A higher incidence of adverse events related to colon
cancerwas alsonoted amongpatients treatedwithprasug-
rel in this study. The reasons for this are unclear, but it is
suggested that this may be due to possible earlier recogni-
tion of otherwise subclinical lesions because of the higher
incidence of bleeding secondary to prasugrel.
Despite its predictable and more effective action com-
pared with clopidogrel, a factor limiting the widespread
use of prasugrel clinically is its cost. At present, the retail
price of prasugrel is about 10 times higher than generic
clopidogrel. In the United Kingdom, prasugrel is currently
recommended as the preferred antiplatelet agent in
patients with low risk of bleeding who are undergo-
ing primary percutaneous coronary intervention for ST
segment elevation myocardial infarction [50].
Ticagrelor
Ticagelor (also known as AZD6140) is a cyclopentyl-
triazolo-pyrimidine [51] and is a very different molecule to
clopidogrel and prasugrel. Ticagrelor is also metabolized
and forms an activemetabolite,ARC124910XX,but this has
very similar pharmacokinetics to the parent compound.
Like the thienopyridines ticagrelor interacts with P2Y12
receptors on platelets rendering them unable to interact
with ADP [52], but in this case the drug does not necessar-
ily require metabolic conversion to interact with the recep-
tor [53].This is likely to at least partly account for the higher
efficacy of ticagrelor over clopidogrel in patients irrespec-
tive of genetic differences in hepatic enzyme activity [54].
The mode of action of ticagrelor and its metabolite is
reversible, in contrast to the irreversible effect of thienopy-
ridines. Consequently, ticagrelor can no longer inhibit
platelet function once its concentration in the blood is
reduced on clearance of the drug from the circulation.The
onset of platelet inhibition is rapid and predictable as
ticagrelor is rapidly absorbed following oral administration
[55]. Its off-rate is surprisingly quite slow despite its revers-
ible mode of action.Although residual platelet inhibition is
less than 50% at 24 h after a dose, approximately 20% inhi-
bition remains at 3 days [56].This may be because ticagre-
lor binds to plasma proteins in the circulation [57], which
can reduce its rate of clearance from the blood. Like clopi-
dogrel, ticagrelor is also a CYP450 substrate and hence
there is the potential for drug–drug interactions [58].
Ticagrelor has been shown to produce a more effective
anti-thrombotic effect compared with clopidogrel. The
PLATO trial [59] was a head-to-head comparison of ticagre-
lor and clopidogrel in patients admitted to hospital with an
acute coronary syndrome.The end result was a significant
reduction in the composite of cardiovascular death, non-
fatal MI and stroke with ticagrelor (hazard ratio 0.84, 95%
confidence interval 0.77, 0.92, P < 0.001), without any dif-
ference in the overall incidence of fatal bleeding or major
bleeding as defined by PLATO criteria as well as using TIMI
(Thrombolysis In Myocardial Infarction) bleeding scores
[60].There was,however, an increase in major bleeding not
related to coronary artery bypass grafting. Of particular
interest, for the first time with a new agent, a significant
reduction in the overall death rate was noted using
ticagrelor in place of clopidogrel. The PLATO PlateLET sub-
study demonstrated that antiplatelet effects were greater
and more consistent with ticagrelor over clopidogrel both
at initiation of treatment and during maintenance therapy
[61]. An unwanted side-effect was an increased incidence
of dyspnoea in the ticagrelor-treated group compared
with the clopidogrel-treated group (discussed later in this
review).
Another potential problem was a geographical varia-
tion in the results of the PLATO trial.The benefits of ticagre-
lor appeared to be attenuated in patients enrolled from
North America. The reasons for this difference are unclear.
This may, of course, have just been a result of the play of
chance, but it is also possible that geographical confound-
ing factorsmay have been involved. It is of note that higher
doses of aspirin were used in the North American patients
compared with the rest of the world. High doses of aspirin
may lead to inhibition of synthesis of naturalmodulators of
platelet function such as the vascular prostaglandins, PGI2,
PGD2 and PGE2, while recent work (see below) has shown
that P2Y12 antagonists can promote the inhibitory effects
of these same natural modulators of platelet function [62].
The possibility that this interaction with high doses of
aspirin could explain the reduced antithrombotic benefits
seen in the North American subgroup warrants careful
consideration.
Ticagrelor has recently been approved for use in
Europe for prevention of atherothrombotic events in
Y. D.Wijeyeratne & S. Heptinstall
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patients with acute coronary syndrome [63], and is cur-
rently under review by the FDA (Food and Drugs Adminis-
tration) regarding approval in the United States.
Cangrelor
Cangrelor (also known as AR-C69931MX) is an ATP ana-
logue and is another direct acting inhibitor of platelet func-
tion acting via the P2Y12 receptor. Cangrelor also acts
in a reversible manner [64]. Unlike ticagrelor, cangrelor
cannot be administered orally, but is being developed for
intravenous use.The half-life of cangrelor is very short and
its effects on platelet function disappear within minutes
following infusion [65].This agentmay thereforebe auseful
therapeutic tool for achieving targeted antiplatelet cover
for defined periods of time according to clinical need [66].
If cangrelor is to be used in this way, intravenously for
short periods of time,cautionwill need to be appliedwhen
switching treatment from cangrelor to another P2Y12
antagonist.This stems from thedifferentmodesof actionof
different antagonists at P2Y12 receptors. For example, it has
been shown that cangrelor,while in contact with the P2Y12
receptor, limits the ability of the clopidogrel activemetabo-
lite or the prasugrel active metabolite to act as irreversible
inhibitors of platelet function [67, 68]. This could have
important clinical implications when switching treatment
from cangrelor infusion to oral clopidogrel or prasugrel. If
oral therapy is initiated early, cangrelor would still be occu-
pying theP2Y12 receptor at the time that theactivemetabo-
lite of clopidogrel or prasugrel appeared in the blood, and
irreversible P2Y12 blockade would not be achieved. Once
the cangrelor was withdrawn the platelets would then
become uninhibited. If, alternatively, administration of the
oral drug is delayed until after cangrelor is withdrawn this
too could lead to a period of absent P2Y12 blockade
between clearance of the reversible agent and availability
of active metabolites from the oral agent. Such a period of
incomplete platelet inhibition could potentially increase
the risk of thrombosis during this period. Further work is
needed to determine the optimal timing and sequence
when switching between different P2Y12 antagonists.
The definitive trials needed to demonstrate the superi-
ority of cangrelor over other P2Y12 antagonists have not
yet been completed or published.Two studies inwhich this
was attempted had disappointing outcomes [69, 70] that
may have resulted from inappropriate trials designs. The
CHAMPION PHOENIX trial is currently underway, evaluat-
ing the efficacy and safety profile of cangrelor compared
with clopidogrel, in patients who require percutaneous
coronary intervention [71].
Elinogrel
A newer P2Y12 receptor blocker currently undergoing
phase II clinical trials is elinogrel (PRT060128), a sulphony-
lurea derivative that too is a direct acting, reversible P2Y12
antagonist. It is the first P2Y12 antagonist being developed
that can be used both as an oral and intravenous agent
[72, 73].
This drug is at a relatively early stage in its develop-
ment. In the new phase II trial, INNOVATE PCI, it was
reported that both the intravenous and oral forms of eli-
nogrel produced greater and more rapid antiplatelet
effects than clopidogrel in stable cardiac patients under-
going percutaneous coronary intervention. This trial,
however,did not demonstrate any difference in the clinical
efficacy of elinogrel over clopidogrel,which may be due to
insufficient statistical power in the study for efficacy out-
comes. It is encouraging to note that therewas no excess in
minor or major bleeding with elinogrel, although there
was a dose-dependent increase in minor bleeds when it
was used during the peri-procedural phase [74].
Further considerations regarding
the mode of action of
P2Y12 antagonists
We have seen above that all the drugs discussed have a
common mechanism of action in that they interact with
the P2Y12 receptor on platelets, reduce the ability of ADP to
interact with that receptor, and thereby reduce platelet
function. Thus there is marked inhibition of platelet func-
tion induced by ADP itself, and also by agents such as
collagen and thrombin,where ADP secreted from platelets
in response to stimulation by these agents contributes to
the overall functional response. P2Y12 antagonists reduce
platelet aggregation, platelet secretion, platelet-leucocyte
interaction and the contribution of platelets to coagula-
tion.P2Y12 antagonists also reduceTXA2 synthesis by plate-
lets and thereby the amplification of platelet functions
mediated by this molecule [75].
But is this the only means through which such drugs
exert their antiplatelet and antithrombotic effects? Also,
are there any additional mechanisms through which par-
ticular drugs might affect platelet function differently
compared with other P2Y12 antagonists?
Are there additional mechanisms through
which P2Y12 antagonists affect
platelet function?
It is interesting to consider whether adenosine production
is relevant to the effects of P2Y12 antagonists. ADP can be
rapidly broken down to AMP and then to adenosine in
blood plasma via ecto-ADPases such as CD39 and CD73
(Figure 2) [76, 77]. Adenosine is an inhibitor of platelet
function acting mainly via A2A receptors on platelets
through which there is stimulation of adenylate cyclase
and an increase in intracellular cAMP. In a recent commu-
nication [78] it was clearly demonstrated that adenosine
derived from ADP breakdown in blood plasma inhibits
platelet function and that adenosine is particularly effec-
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tive as an inhibitor of platelet function in the presence of a
P2Y12 antagonist [78]. P2Y12 antagonists reduce inhibition
of adenylate cyclase (Figure 2), so perhaps it is not surpris-
ing that an agent that increases cAMP does somore readily
in the presence of a P2Y12 antagonist and this does prove
to be the case. So might part of the action of a P2Y12
antagonist, and indeed the clinical benefit to be derived
from their use, be mediated via adenosine?
An important consideration is that adenosine is rapidly
transported into red cells via the equilibrative nucleoside
transporter and this makes the adenosine unavailable
to interact with platelets (Figure 2). Thus experiments
performed in whole blood (i.e. with red cells present) pro-
vided very different results to those obtained in platelet-
rich plasma (i.e. with red cells absent). In whole blood any
inhibitory effects of adenosine produced from ADP could
not be seen. Inhibition of platelet aggregation could only
be seen in whole blood when the action of the equilibra-
tive nucleoside transporter was blocked using dipy-
ridamole [78]. There is still the possibility, though, that
adenosine could be important in vivo, possibly at sites of
thrombus formation or haemostasis where, for haemody-
namic reasons, red cells may be excluded.
In considering a possible role for adenosine in deter-
mining the effects of P2Y12 antagonists on platelet func-
tion, it is pertinent to consider separately the situationwith
ticagrelor.This drug has been reported to inhibit the equili-
brative nucleoside transporter in addition to its ability to
act as a P2Y12 antagonist (Figure 2) [79]. Indeed, this is
believed to be a possible explanation of the occurrence of
dyspnoea observed in clinical trials involving this drug, a
condition that is thought could be a consequence of raised
adenosine concentrations in the circulation [80]. So, in
theory, by both blocking the equilibrative nucleoside
transporter and by acting as a P2Y12 antagonist ticagrelor
should provide more effective inhibition of platelet aggre-
gation in whole blood than other P2Y12 antagonists.
However, when this was looked for [71], it was found that
the effects of ticagrelor on platelet aggregation in both
platelet rich plasma and in whole blood were exactly the
same as for cangrelor and the prasugrel active metabolite.
For all three P2Y12 antagonists studied, adenosine pro-
duced from ADP inhibited platelet aggregation in platelet-
rich plasma but not in whole blood. This finding does not
support an additional mode of action of ticagrelor on
platelet function via inhibition of adenosine uptake.
P2Y12 antagonists may also promote the inhibitory
potency of some other naturalmodulators of platelet func-
tion in addition to adenosine (Figure 3). In this regard, it has
already been shown that prostaglandin E1 (PGE1) is a better
inhibitor of platelet aggregation in the presence of cangre-
lor or clopidogrel than in the absence of one of these P2Y12
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Figure 2
Mechanisms involved in adenosine production and removal, and the way in which adenosine interacts with platelets to increase cAMP and inhibit platelet
aggregation. The points at which a P2Y12 antagonist and dipyridamole influence the pathways are shown. Recent research does not support an effect of
ticagrelor at the equilibrative nucleoside transporter (ENT) [78]
Y. D.Wijeyeratne & S. Heptinstall
652 / 72:4 / Br J Clin Pharmacol
antagonists [81]. Also prostaglandin I2 (PGI2) acting
through the IP receptor has been shown to be a better
inhibitor of platelet aggregation in the presence of cangre-
lor [82]. More recently further studies were performed on
the effects of cangrelor on the ability of various prostag-
landins, PGD2, PGE1, PGE2, PGE3, PGI2 and the PGI2 mimetic
iloprost to inhibit platelet aggregation. In all cases cangre-
lor potentiated the dose-dependent inhibition of platelet
aggregation by some 3–10-fold,meaning that much lower
concentrations of the prostaglandins were needed to
inhibit the aggregation response [62]. This effect was not
limited to cangrelor since ticagrelor and the prasugrel
active metabolite produced similar potentiating effects.
Interestingly, potentiation of the effects of these natural
prostaglandins in the presence of a P2Y12 antagonist out-
weighed the ability of a P2Y12 antagonist used alone to
inhibit platelet aggregation. This may be a major finding
regarding the mechanism through which P2Y12 antago-
nists bring about clinical benefit, and requires further
investigation. We have already speculated (above) on the
possible implications of this finding for the geographically
different outcomes of the PLATO study.
Another interesting finding in the study described
above [62] was the ability of the EP3 receptor antagonist
DG-041 to potentiate the inhibitory effects a P2Y12 antago-
nist used in combination with either PGE1 or PGE2.Previous
observations on the ability of DG-041 to modulate the
effects of PGE2 on platelet function and thrombus forma-
tion have suggested that this EP3 antagonist may produce
a useful additional therapy for atherothrombosis [83–85].
There are a number of potential additional effects of
particular P2Y12 antagonists that have received consider-
ation and investigation,but so far there is no certainty that
any such additional effects exist or have any bearing on the
effectiveness or otherwise on the outcomes of therapy.
The mode of action of clopidogrel and prasugrel at
P2Y12 receptors could mean that these drugs also affect
other receptors in addition to P2Y12 receptors.Other recep-
tors in the 7TM class have cysteine residues within them
that could interact with the active metabolites of these
two drugs [86]. Effects at such receptors could either
promote or inhibit their function.This possibility prompted
a study [87] to look for any evidence of effects of the pra-
sugrel active metabolite at a number of G-receptors on
platelets and to compare the results with those for ticagre-
lor and cangrelor. The authors looked for any ability of the
P2Y12 antagonists to modify the effects on platelet aggre-
gation of a number of agonists and antagonists known to
act at a variety of such receptors, all under circumstances
where the role of P2Y12 receptors were diminished by
working under conditions where any ADP or metabolites
of ADP were purposely removed. However, no effects of
any of the P2Y12 antagonists at receptors other than P2Y12
receptors could be detected.The receptors that were unaf-
fected by the P2Y12 antagonists were the PAR1 receptor,
the TP receptor, the IP receptor, the A2A receptor and the EP
receptors.These mediate the effects on platelets of throm-
bin, TXA2, PGI2, adenosine and PGE2, respectively,
The lack of effects of cangrelor at receptors other than
P2Y12 is also worthy of note because it had been reported
previously that cangrelor was able to inhibit platelet
aggregation through interaction with an unidentified
Gs-coupled receptor leading to increased cAMP concentra-
tions [88]. Indeed these authors argued that this may be
the main mode of action of cangrelor rather than through
P2Y12 blockade. However Iyu et al. [87] were unable to rep-
licate the marked inhibition of aggregation induced by
agents other than ADP or the increases in cAMP observed
previously and thereby found little evidence for a direct
effect of cangrelor at receptors other than P2Y12 receptors
on platelets.They concluded that large quantities of ADP in
the platelet preparations may have lead to misleading
interpretations of the data obtained previously.
Conclusions
The P2Y12 receptor antagonists clopidogrel, prasugrel and
ticagrelor are already in clinical use as antithrombotic
agents. Variability in antiplatelet effectiveness translating
into poor clinical outcomes is a particular problem with
clopidogrel, the most widely used and economical ADP
receptor antagonist available at present. This makes it
crucial to be able to measure the antiplatelet response in
individual patients. Platelet function tests are becoming
available for clinical use, and these together with the
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Figure 3
The receptors with which some natural modulators of platelet function
interact to either increase or decrease cAMP and thus inhibit or promote
platelet aggregation.The points at which a P2Y12 antagonist and the EP3
antagonist DG-041 influence the pathways are shown
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choice of different ADP receptor antagonists available,may
allow tailored antiplatelet therapy to be given to individual
patients for optimal effect to reduce thrombotic risk.
Newer agents with distinct properties are in development
and may offer additional therapeutic options. Research
is ongoing to gain more information on interactions
between P2Y12 receptor antagonists and natural agents
that may contribute to inhibition of platelet function, and
also to look for any differences in mechanism of action
between the different agents that are already available
and in development.
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